Total: $172.15M |
||||
Company | Type Of Financing | Number | Amount | Investors; Placement Agents; Details (Date)@ |
| | ||||
Altachem Pharma Ltd. (Canada;CDNX:AAF) | Private placement of units | 8.5U | C$10.2 | Altachem raised US$6.4M in a private placement of 8.5M units (3/1) |
Amrad Corporation Ltd. (Australia; ASX:AMC) | Private placement of common stock | N/A | A$15.5 | Amrad raised US$7.9M from institutional investors (3/6**) |
AVI BioPharma Inc. (AVII) | Private placement of common stock | 2.9S | $22 | AVI raised $22M in the sale of 2.9M shares at $7.50 per share to institutional investors (3/26) |
Boston Life Sciences Inc. | Private placement of common stock | N/A | $3.4 | Boston Life Sciences completed the $3.4M private placement with a small group of individual and institutional investors (3/12) |
Cell Pathways Inc. (CLPA) | Private placement of common stock | 2.4S | $8.84 | Cell Pathways sold 2.4M shares, raising $8.84M; buyers also received with each share a warrant to buy one-quarter of a share at an exercise price of $4.74 (3/27) |
Cypress Bioscience Inc. (CYPB) | Private placement of common stock and warrants | 6.9S and W for 3.4S | $17 | Cypress sold 6.9M shares and warrants to purchase up to about 3.4M shares of common stock, for a total of $17M; institutional and other accredited investors purchased the stock and warrants (3/26) |
Cytovax Biotechnologies Inc. (Canada; TSE:CXB) | Private placement of common stock | 2.7S | C$8 (US$5.02) | Cytovax raised US$5.02M in a private placement with a syndicate of agents co-led by Dlouhy Merchant Group Inc. and First Associates Investments Inc., and including Sprott Securities Inc. (3/26) |
DepoMed Inc. (AMEX:DMI) | Private placement of common stock | 2.3S | $8.8 | DepoMed raised $8.8M for the sale of 2.3M shares to new and existing institutional and other accredited investors; Fahnestock & Co. Inc. acted as placement agent (3/25) |
Genome Therapeutics Corp. (GENE) | Private placement of convertible debentures | N/A | $15 | Genome Therapeutics raised $15M in the financing with two institutional investors (3/6) |
IGEN International Inc. | Private placement of common stock | 1S | $36.8 | IGEN raised $36.8M with the sale of 1M shares to Acqua Wellington Private Placement Fund Ltd. and Acqua Wellington Opportunity I Ltd. (3/12) |
NeoTherapeutics Inc. (NEOT) | Private placement of common stock | 4.02S | $8.05 | NeoTherapeutics raised $8.05M with the placement of shares at $2 each with a group of institutional and individual investors (3/19) |
Orchid BioSciences Inc. (ORCH) | Private placement of common stock | 1S | $2.5 | Orchid's underwriter, Robertson Stephens Inc., in its recent offering exercised an overallotment option to purchase an additional 1M shares, bringing the total amount raised to $22.5M (3/6) |
Oxis International Inc. (OTC BB:OXIS) | Private placement of convertible preferred warrants | W for 1.5S | $1.5 | Oxis raised $1.5M in a financing by Meridian Financial Group LLP (3/20) |
Paladin Labs Inc. (Canada;TSE:PLB) | Private placement of special warrants | 2.2W | C$21 (US$13.24) | Paladin Labs raised US$13.24M in a placement of 2.2M special warrants; agents for the placement were CIBC World Markets Corp., Yorkton Securities Inc. and Desjardins Securities Inc., as well as BMO Nesbitt Burns Inc., National Bank Financial Inc. and Sprott Securities Inc.; the agents have an overallotment option for another 315,800 special warrants, or $3M (3/22) |
Questcor Pharmaceuticals Inc. (AMEX:QSC) | Private placement of convertible debentures and warrants | W for 1.5S | $4 | Questcor raised $4M through the issuance of 8% convertible debentures due in 2005 to SF Capital Partners and Defiante Farmaceutical Unipessoal L.d.a.; the debentures are convertible into shares at a fixed conversion price of $1.58 per share; Questcor also issued warrants to purchase up to an aggregate 1.5M shares of common stock at $1.70 per share (3/19) |
RegenRx Biopharma- | Private placement of common stock | 7.3S | $1.7 | RegenRx raised $1.7M in a financing led by Defiante Farmaceutica Unipessoal L.d.a. (3/11) |
ViroLogic Inc. | Private placement of preferred stock | N/A | $10 | ViroLogic raised $10M in the placement with several large investors (3/26) |
| | ||||
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. This chart does not include real estate or manufacturing plant financings. |
||||
@ Dates refer to the date of the press release. |
||||
** Denotes the date the item ran in BioWorld International. |
||||
N/A = Not available, applicable or reported. |
||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange |
||||
